Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APPS-H0006
- Development stage
- Preclinical
- Lead developer
- Apichope Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
APPS-H0006 is a small molecule drug candidate being developed by Apichope Pharmaceutical for the treatment of cardiovascular and cerebrovascular diseases. Currently in the preclinical stage of development, the drug is formulated as an oral tablet. While the specific biological target and mechanism of action remain proprietary and have not been publicly disclosed, it represents a key component of Apichope's research and development efforts in the field of chronic disease management and vascular health.
- Other names
- APPS-H0006 tabletAPPS-H-0006 tabletAPPS-H 0006 tablet
Beyond the preview
Go deeper on APPS-H0006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APPS-H0006.